文献速递胸部肿瘤头颈与中枢神经肿瘤

欧洲非小细胞肺癌脑转移筛查与管理多样性:EORTC肺癌组调查结果

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
PubMed 文献 · Eur J Cancer · 2018-02-21

结果显示筛查不统一,预后分类使用少,驱动基因突变患者更常接受强化局部治疗,需前瞻性评估其管理。

要点

  • 85%医生对初诊无症状患者筛查脑转移,52%使用MRI。
  • 仅34%医生使用预后分类指导初始治疗决策。
  • 驱动基因突变且脑转移>4个者更可能接受立体定向放疗(27% vs 21%,p<0.01)。

核心结论

  • 欧洲NSCLC脑转移管理差异大:筛查不统一,预后分类少用,驱动基因突变患者局部治疗更强化。

研究设计与样本

  • 分析462名欧洲医生(394家机构)的回复,其中放疗科53%、呼吸科26%、肿瘤内科18%,84%有>5年NSCLC经验。

主要发现

  • 393名医生(85%)在初诊时对神经无症状患者筛查脑转移,其中52%使用磁共振成像。
  • 最常筛查的人群为驱动基因突变者(51%)、III期(63%)和IV期(43%)。
  • 158名医生(34%)使用预后分类指导初始治疗,其中50%在驱动基因突变与非突变患者间采用不同的最低预后评分阈值。
  • 驱动基因突变且脑转移>4个的患者比非突变者更可能接受立体定向放疗(27% vs 21%,p<0.01)。
  • 90%医生可及立体定向放疗;单发脑转移术后50%常规处方立体定向放疗或全脑放疗,45%仅在不完全切除时处方。

关键数值与推荐

  • 神经无症状初治且脑转移>5个的患者首选全身治疗(79%医生)。
  • 立体定向放疗/全脑放疗期间,45%和49%医生停用所有酪氨酸激酶抑制剂和免疫检查点抑制剂(时机不一)。
  • 最常继续使用的药物:厄洛替尼(44%/40%)、吉非替尼(39%/34%)、阿法替尼(29%/25%)、克唑替尼(33%/26%)和抗PD-(L)-1(28%/22%)。

临床怎么用

  • 应统一脑转移筛查策略,尤其在驱动基因突变和III/IV期患者中。
  • 需推广预后分类工具以指导初始治疗决策。
  • 驱动基因突变患者脑转移局部治疗更积极,但靶向/免疫药物与放疗联合的最佳时序和停药策略尚不明确。

局限性

  • 未报告各治疗策略与患者结局的关联。
  • 问卷回复率及代表性未报告,结果可能不能推广至全球。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain metastases (BM) are frequent in non-small cell lung cancer (NSCLC) patients, but there is a lack of evidence-based management of this patient group. We aimed to capture a snapshot of routine BM management in Europe to identify relevant research questions for future clinical trials. METHODS: An EORTC Lung Cancer Group (LCG) online survey containing questions on NSCLC BM screening and treatment was distributed between 16/02/17 and 15/06/17 to worldwide EORTC LCG members, and through several European scientific societies in the thoracic oncology field. RESULTS: A total of 462 European physician responses (394 institutions) were analysed (radiation oncologist: 53% [n = 247], pulmonologist: 26% [n = 119], medical oncologist: 18% [n = 84]; 84% with >5 years' experience in NSCLC). Italy (18%, n = 85), Netherlands (15%, n = 68), UK (14%, n = 66), and France (12%, n = 55) contributed most. 393 physicians (85%) screened neurologically asymptomatic patients for BM at diagnosis (52% using magnetic resonance imaging). Most often screened patients were those with a driver mutation (MUT+; 51%, n = 234), stage III (63%, n = 289), and IV (43%, n = 199). 158 physicians (34%) used a prognostic classification to guide initial treatment decisions, and in 50%, lowest prognostic-score threshold to receive treatment differed between MUT+ and non-driver mutation (MUT-) patients. MUT+ patients with >4 BM were more likely to receive stereotactic radiosurgery (SRS) compared with MUT- (27% versus. 21%; p < 0.01). Most physicians (90%) had access to SRS. After single BM surgery, 50% systematically prescribed SRS or WBRT, and 45% only in case of incomplete resection. The preferred treatment in neurologically asymptomatic treatment-naive patients diagnosed with >5 BM was systemic treatment (79%). Of all, 45%/49% physicians stated that all tyrosine kinase inhibitors and immune checkpoint blockers were discontinued (timing varied) during SRS/WBRT, respectively. Drugs most often continued during SRS/WBRT were erlotinib (44%/40%), gefitinib (39%/34%), afatinib (29%/25%), crizotinib (33%/26%) and anti-PD-(L)-1 (28%/22%). CONCLUSION: BM management is highly variable in Europe: screening is not uniform, prognostic classifications are not often used and MUT+ NSCLC patients generally receive more intensive local treatment. Prospective assessment of BM management in MUT+ NSCLC patients is required.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Levy A, Faivre-Finn C, Hasan B, et al. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. Eur J Cancer. 2018. PMID: 29477100. doi:10.1016/j.ejca.2018.01.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。